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Background and Objective. The veno-occlusive
disease of the liver (VOD) is a disorder caused by
the non-thrombotic occlusion of the central veins
of hepatic lobules. The clinical features are similar
to those of intrahepatic portal hypertension (unex-
plained weight gain, ascites, painful hepatomegaly,
jaundice). In the past, this disease was rather infre-
quent and was linked to the absorption of toxic
agents, liver irradiation or chemotherapy.
However, the intensification of treatment proto-
cols before hematopoietic stem cell transplants
has considerably increased its incidence. The
strategies used for its prevention and treatment
remain limited in efficacy. The present review was
undertaken in order to assess progress in the diag-
nosis and management of this severe complication
in stem cell transplantation.
Information Sources. The method used for
preparing this review was an examination of 250
relevant articles or abstracts published in journals
covered by Medline®.
State of Art. Despite the progress made toward the
understanding of its physiopathology and the iden-
tification of its risk factors, VOD is still one of the
leading causes of morbidity and mortality during
the first two months post-BMT, and therefore often
constitutes a limitation for the further increment of
the dose of antineoplastic drugs. This may be
explained by the difficulty in making an early diag-
nosis of this problem, at a time when therapeutic
intervention may be more effective, and, on the
other hand, the lack of a well-established prevention
and treatment approach for patients with VOD. 
Perspectives and Conclusions. New diagnostic
procedures, such as laparoscopic liver biopsy, and
new therapeutic approaches, such as transjugular
intrahepatic portosystemic shunting (TIPS) or defi-
brotide, are now being evaluated. However, addi-
tional studies will be needed to determine the
most appropriate therapy for each VOD patient
depending on the severity of the disease.
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T he veno-occlusive disease of the liver (VOD)results from a hepatotoxic lesion causing theobstruction of small intrahepatic venules,
hence leading to lesions in the central zone hepato-
cytes and surrounding sinusoids.1 Although the dis-
ease was first described in some Jamaicans who
habitually consumed local herb infusions contain-
ing pyrrolizidine alkaloids (senecio),2 nowadays
VOD is above all a serious complication of bone
marrow transplants (BMT). Its incidence varies
considerably from 3% in pediatric centers that per-
form allogeneic transplants in children with tha-
lassemia major,3 to more than 65% in centers that
carry out bone marrow transplants in cases of
advanced hematological disorders.4 However, the
incidence of VOD varies among these centers,
depending on their capacity to diagnose early and
mild VOD. The Seattle5-7 and Baltimore8 groups
have set up similar clinical diagnostic criteria for
VOD (Table 1). Patients who meet modified Seattle
criteria6,7 are retrospectively classified for severity in
three groups (mild, moderate and severe VOD)
based on their outcome (Table 2). In a cohort
study of 355 patients,9 mild, moderate and severe
VOD occurred respectively in 12%, 26% and 15% of
the patients, and their mortality rates before day
100 were 9%, 23% and 98%, respectively. In this
article, we will review the pathophysiology and vari-
ous risk factors of this disease, describe its clinical,
biological and anatomical aspects, and present
options for its prevention and treatment.
Pathophysiology
Although the exact sequence of events leading to
the clinical manifestations of VOD is still debated,
the earliest event seems to be damage to the hepat-
ic venular and sinusoidal endothelium, which local-
ly induces a hypercoagulable state by activating the
coagulation cascade and favoring clot formation
over natural anticoagulation.1,7,10-13 Consequently,
the venular and sinusoidal lumen is reduced due to
an edematous concentric subendothelial zone con-
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taining fragmented red cells, debris and fibrillar
material, thus inducing partial to complete fibrotic
obliteration of the venular lamina.7 Systemic abnor-
malities of coagulation proteins have been
observed, either before conditioning in patients
who will later develop VOD or after high-dose
chemo- or radiotherapy.13,14 The main issue regard-
ing these data is discovering whether these coagula-
tion parameters are involved in the pathogenesis of
VOD or if they are merely consequences of the dis-
ease. Several cytokines, such as TNF-a, IL-1 or TGF-
b have been implicated on the basis of their known
effects on endothelial cells and because of their ele-
vated levels in patients before the onset of hepatic
dysfunction associated with VOD.15,16 Although
endothelial cells appear to be the primary target of
events leading to VOD, hepatocytes also play a crit-
ical role. Centrilobular (zone 3) hepatocytes con-
tain cytochrome P 450 enzymes that metabolize
many of the chemotherapeutic agents used in con-
ditioning regimens for BMT. Some drugs are trans-
formed into toxic metabolites and then converted
into stable metabolites by glutathione and glu-
tathione-dependent enzymes that are present in
only low concentration in centrilobular hepato-
cytes. Thus, when a drug that potentially gives rise
to toxic metabolites is administered together with
agents that reduce glutathione, there is a high
probability of centrilobular hepatocyte injury and
sinusoidal damage.7,17
Risk factors for VOD
The occurrence of VOD is linked to a number of
factors among which we can distinguish pre-trans-
plant risk factors, risk factors associated with the
conditioning regimen, and risk factors linked to the
type of transplant.
Pre-transplant risk factors
The following risk factors are currently considered
as being significantly associated with VOD: elevated
transaminase levels before the beginning of the
conditioning regimen;9 treatment for viral or bacter-
ial infections at the beginning of the conditioning
regimen;9 liver metastases18 or previous liver irradia-
tion.9 Prior cumulative exposure to high doses of
cytotoxic agents may contribute to these risks.
Thus, a second marrow transplant preceded by a
second conditioning treatment is often complicat-
ed by VOD.9 The contribution of the hepatitis C
virus (HCV) to VOD is controversial. One study19
suggested that patients with liver disease caused by
HCV infection are at a high risk of developing lethal
VOD after BMT, but another report20 in a selected
and homogeneous population did not confirm the
association.
Risk factors related to the conditioning regimen
Nearly all preparative regimens before a hemato-
poietic stem cell transplant can cause VOD, particu-
larly the most intensive ones.9,11 Nevertheless, some
conditioning protocols seem to be more toxic than
others. For instance, the association of cyclophos-
phamide and busulfan has been shown to cause
VOD more than the association of cyclophos-
phamide and total body irradiation.21 However,
some recent reports do not show such an associa-
tion.22,23 The technique of total body irradiation
administered may also be important since fraction-
ating the dose could significantly reduce the risk of
VOD24 in one study, but not in another.25 The total
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Table 1. Clinical criteria for the diagnosis of VOD.
1) Seattle criteria (see ref. #5)
Presence, before day 30 after transplant, of at least two of the fol-
lowing features:
1. jaundice
2. hepatomegaly and right upper quadrant pain
3. ascites and/or unexplained weight gain 
2) Baltimore criteria  (see ref. #8)
Hyperbilirubinemia ‡ 2 mg/dL (34.2 µmol/L) before day 21 after
transplant and, at least, two of the following features:
1. hepatomegaly (usually painful)
2. ascites
3. weight gain greater than 5% from baseline
3) Modified Seattle criteria (see refs. #6, 7)
Occurrence of two of the following events within 20 days of trans-
plantation:
1. hyperbilirubinemia (total serum bilirubin > 2 mg/dL)
2. hepatomegaly or right upper quadrant pain of liver origin
3. unexplained weight gain (> 2% of baseline body weight) 
because of fluid accumulation.
Table 2. Classification of VOD according to its severity.9
1) Mild VOD
Patients have mild VOD if:
1. they show no adverse effect from liver disease
2. they require no treatment for VOD
3. their illness is self limited
2) Moderate VOD
Patients have moderate VOD if:
1. they have an adverse effect from liver disease
2. they require treatment for VOD (such as diuretics for fluid
retention or medication to relieve pain from
hepatomegaly)
2) Severe VOD
Patients have severe VOD if:
1. their VOD does not resolve before day 100
2. they die of VOD
dose of radiation received by the patient is also cor-
related with VOD.9 The liver toxicity of busulfan
clearly appears to be related to its pharmacokinet-
ics: Grochow et al. originally correlated VOD with
increased mean busulfan area under the curve of
concentration vs. time (AUC) (>2012 µMol/
min/L).26 A later prospective study by the same
group27 confirmed an increased occurrence of VOD
with AUC > 1500 µmol/min/L, and showed that
adaptation of the dose according to the AUC signif-
icantly reduced the risk of VOD. However, one
study28 was unable to correlate the risk of VOD with
Busulfan pharmacokinetic parameters, and two
additional papers29,30 reported that the adjustment
of the dose according to the AUC failed to reduce
VOD frequency.
Type of transplant
Contrary to what is commonly believed, multivari-
ate analyses have shown that the incidence of VOD
after allogeneic BMT is not higher than its incidence
after autologous BMT.9 Nevertheless, the relative
risk of severe VOD was found to be 2.15 times high-
er in mismatched family or unrelated allogeneic
recipients as compared to HLA-identical sibling
transplants.6 The use of methotrexate as prophylaxis
of GVHD is associated with an increased risk of
VOD as compared to the use of cyclosporine alone
or together with corticosteroids.4
Clinical aspects
Clinical history
Usually, an unexplained weight gain is the first
symptom of VOD. This weight gain, attributable to
water and sodium retention by the kidney, appears
within 6 to 8 days following the transplant in 95%
of patients that develop VOD.12 Two to three days
later, hyperbilirubinemia of varying degrees is
observed in 98% of the cases.12 An increase in aspar-
tate aminotransferase and alkaline phosphatase
may occur simultaneously or a few days later. Most
patients develop ascites and pain in the upper right
quadrant, and clinical examination usually reaveals
a firm and painful hepatomegaly. Many patients
become refractory to platelet transfusions.7,11-12
Renal insufficiency is also present in 50% of patients
developing VOD (mainly patients with severe VOD)
and 25% of them will require hemodialysis.12,31
Finally, patients with severe VOD can display severe
encephalopathy or even become comatose.
Outcome
In 50 to 80% of the cases, a gradual improvement
of the clinical condition is noted at 2 to 4 weeks
after the onset of the disease.6,12 In the remaining 20
to 50% of the cases, patients die because of or with
severe VOD. The majority of them die of multiple
organ failure (MOF) with hepatic failure, but also
of renal failure, congestive heart failure, extravascu-
lar fluid effusions, and pulmonary failure requiring
oxygen support and mechanical ventilation.6 The
reasons for lung failure may include pulmonary
VOD, pleural effusions and interstitial pneumonitis
of infectious or non-infectious origin.31,32 Bleeding
at gastrointestinal sites or at other sites is a signifi-
cant cause of death as well. The Seattle group33 has
developed an elaborate regression model that esti-
mates the probability of developing severe (mortal)
VOD based on early measurements of serum biliru-
bin and the percent of weight gain. However, the




Although theoretically the diagnosis of VOD
should be based on the histological examination of
the liver, the risk of bleeding during a liver biopsy in
thrombopenic patients who are often refractory to
platelet transfusions is such that the diagnosis is
very often only a clinical one. The Seattle5 and
Baltimore8 groups have set up similar diagnostic
criteria for VOD (Table 1). Although the diagnostic
accuracy of these protocols is excellent when all cri-
teria are met, other groups have found that their
sensitivity and specificity diminish in the early diag-
nosis of VOD when only 2 criteria are present.34
However, in this case, a liver biopsy is not very sen-
sitive, partly because of the heterogeneity of VOD
lesions throughout the liver. It is not yet clear
whether the modification of the Seattle criteria
(Table 1) will improve their sensitivity and specifici-
ty. Patients who meet modified Seattle criteria for
VOD but have another cause of liver dysfunction
(Table 3) or patients who meet only one of the
modified Seattle criteria all have liver dysfunction of
uncertain causes. In McDonald’s study of 355
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Table 3. Differential diagnosis of VOD.
1) After allogeneic BMT:
1. Acute liver GVHD
2. Cyclosporine-induced hepatotoxicity
2) After autologous or allogeneic BMT:
1. Fungal infiltration of the liver
2. Viral hepatitis
3. Cholangitis lenta, e.g. during sepsis
4. Drug  (trimethoprim-sulfamethoxazole, some third-generation 
penicillins, fluconazole and itraconazole) induced liver dysfunction
5. Constrictive pericarditis and right congestive heart failure
6. Persistent tumor infiltration of the liver
patients,9 72 patients (22%) were classified as hav-
ing liver disease of an uncertain cause. The reasons
for this classification are shown in Table 4.
Differential diagnosis
Other liver diseases are common after BMT
(Table 3). However, the presence of weight gain
and fluid retention is usually sufficient to differenti-
ate VOD from other causes of early liver dysfunc-
tion. 
Acute liver GVHD causes jaundice with increased
serum alkaline phosphatase and aminotransferase
levels. Ascites, liver failure and encephalopathy are
unusual. AGVHD usually develops between days 20
and 40 post-transplant together with skin and/or
gut GVHD.35 However, the differential diagnosis
with VOD can be difficult when GVHD develops
earlier (hyperacute GVHD) or when the onset of
VOD is later than day 10. Moreover, both diseases
are common after allogeneic BMT and may thus
coexist. In this case, measurement of the hepatic
venous pressure and/or a histologic evaluation of
the liver may be helpful in determining which dis-
ease is dominant.  
Fungal infiltration of the liver usually causes ten-
der hepatomegaly, fever, and markedly elevated
serum alkaline phosphatase levels36 (which are
unusual with VOD). However, fungi (mainly
Candida species) can also invade blood vessels,
causing hepatic infarctions or venous obstructions
that produce tender hepatomegaly, ascites and
signs of portal hypertension mimicking VOD.37 Viral
infections of the liver are unusual in the early post-
transplant period because of the systematic use of
acyclovir and because B and C hepatitis viruses can
produce liver injury only in the presence of an intact
immune system.11 Cholangitis lenta follows sepsis
and other causes of cytokine release. The bilirubin
level can exceed 10 mg/dL, but ascites, weight gain
and renal failure are unusual.
Medications used in the transplant setting can
also induce liver dysfunction. Cyclosporine, in a
dose-dependent fashion,35 may cause cholestasis
and hepatocyte necrosis and lead to gallstones.
Total parenteral nutrition, some antimicrobial
drugs (such as trimethoprim-sulfamethoxazole,
some third-generation penicillins, fluconazole and
itraconazole) and methotrexate can produce both
cholestasis as well as hepatocellular injury as well.
Constrictive pericarditis and right congestive
heart failure can cause pain in the upper right
quadrant, hepatomegaly, ascites, peripheral edema
and pleural effusions, as well as renal failure and an
increase in the concentration of serum hepatic
enzymes. Both diseases can be ruled out by normal
echocardiography. 
Finally, in patients with refractory disease, persis-
tent tumor infiltration of the liver should be consid-
ered. 
Histology
When the diagnosis cannot be made clinically
(because the timing of symptoms is modified by
therapies affecting the natural evolution of the dis-
ease, or only two out of the 3 Seattle criteria are pre-
sent, or clinical data suggest another cause of hepat-
ic disorder), and aggressive therapy is required, a
transjugular liver biopsy can be carried out.38 This
further allows for the measurement of the hepatic
venous pressure gradients (HVPG), which favor VOD
if greater than 10 mm Hg,38,39 and shows a high
prognostic value. However, because of the risk of
bleeding which may be fatal or preclude beneficial
therapy, and because of low sensitivity in patients
not meeting clinical criteria, the role of transjugular
liver biopsy is still debated. It should be noted that
the risk of complications after measurement of
HVPG alone (without liver biopsy) is low, and this
may be useful in differentiating VOD from GVHD.
Another interesting approach is the laparoscopic
liver biopsy.40 This technique was recently evaluated
in a group of 29 patients, including 24 BMT recipi-
ents, with hepatic dysfunction after chemotherapy.
Thirty-two biopsies were obtained and all were infor-
mative. Furthermore, no procedure-related compli-
cation was noted and no patient required re-explo-
ration. 
From the histologic standpoint (Figure 1), the
most distinctive feature of VOD is a thickening of
the subintimal zone of central and sublobular
venules, producing concentric or eccentric luminal
narrowing.41-43 In the early stages, the changes con-
sist of a marked widening of the subendothelial
zone by fragmented red cells within an edematous
proliferation where fibrinogen can be identified by
a special stain (Mallory’s stain, Lendrum’s MSB
technique) or immunochemistry.44 Thrombosis
does not occur and inflammatory cells are few or
absent. These obliterative lesions are focally distrib-
uted and can be obscured by the background fea-
tures of acute venous outflow obstruction; they
show pronounced centrilobular congestion, sinu-
soidal dilatation and hepatocyte loss. Therefore,
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Table 4. Reasons for assigning patients to the group of liver dis-
ease of  «uncertain cause» in the McDonald’s study (ref. #9).
Signs of VOD not meeting modified Seattle criteria:  35% 
Other liver disease within 20 days of bone marrow infusion: 
• sepsis: 28%
• GVHD: 22%
• cardiac failure: 8%
• persisting tumor infiltration of the liver: 4%
Died before liver disease could become clinically apparent: 4%.
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these early lesions can be missing or inconspicuous
on routine stains, and the changes can be difficult
to distinguish from sinusoidal congestion.
Connective tissue stains (trichrome techniques)
may help their identification.
In later stages, the subintimal lesion becomes
fibrotic and can acquire an ingrowth of small vas-
cular channels (Figure 2). Eventually the affected
venules are incorporated into the centrilobular
fibrous scarring and can only be identified by con-
nective tissue stains. Change in chronic venous out-
flow obstruction dominates the histological pic-
ture: perivenular fibrosis, pericellular fibrosis and
central-central fibrous bridges develop and cirrhosis
may ultimately appear. These late changes are non-
specific and can be seen in other types of chronic
outflow obstruction and cirrhosis as well.
Hepatocyte hyperplasia of varying degrees and
peliosis hepatis have occasionally been found to
accompany VOD and are particularly prominent in
azathioprine-treated renal transplant patients.42
Connective tissue usually consists of a cellular
portion in an enveloping framework of non-cellular
substances, either of fibrous (collagen, reticular
and elastic fibers), amorphous or gel types. A
detailed review of the biochemical principles for
staining of these substances is beyond the scope of
this article.45 Many techniques are available for the
differential analysis of the connective tissues, the
most frequently used being the Van Gieson and
Masson trichrome techniques (Figures 1 and 2).
Trichrome stains, which employ three dyes, allow
for the selective demonstration of muscle, collagen
fibers, fibrin and erythrocytes. Three methods selec-
tively demonstrate fibrin: Gram-Weigert, Mallory’s
phosphotungstic acid, hematoxylin and Masson’s
trichrome modified after Lendrum. Demonstration
of elastic fibers is best achieved by the following
techniques: Verhoeff, orcein, Weigert’s resorcin
fuchsin and aldehyde fuchsin. Reticular fibers are
best demonstrated by techniques that use silver
salts, such as Gordon and Sweet’s method or
Gomori’s method.
Other investigations
Other than the clinical picture and the histology,
ultrasound studies may help in diagnosis by show-
ing ascites, hepatomegaly or thickening of the gall-
bladder wall, which are, in any case, all non-specific
or unreliable findings. Pulsed Doppler ultrasound
may show a decreased or inverted portal blood
flow but this is a relatively late finding in patients
with established VOD.46 A prospective study from
Seattle46 was not able to identify any sonographic
feature strongly associated with VOD in the early
phases of the disease, when a definitive diagnosis is
most needed. 
Several laboratory parameters have been studied
as potential markers of VOD. Serum procollagen
III47 or its N-terminal peptide48 have been found to
be early markers of VOD even before any clinical
sign of the disease. Contrary to protein S and
antithrombin III, low protein C levels can discrimi-
nate between patients with or without VOD, but
this is a predictive test rather than a specific mark-
er, because the difference between the two groups
is already evident before conditioning.13 Finally, a
recent study49 has shown that the level of plasmino-
gen activator inhibitor 1 (PAI-1) was significantly
elevated at the time of bilirubin increase in patients
with VOD as compared with patients with GVHD
or other causes of hepatic damage.
Prevention 
Given the very high mortality rate in patients with
severe VOD, it is critical to prepare effective preven-
tive strategies during hematopoietic stem cell trans-
plants. Preventive measures have essentially been
based on four different molecules: heparin,
Figure 1. Masson trichrome X 250 showing early stages of VOD.
Concentric luminal narrowing of centrilobular venules by
subendothelial edema and accumulation of fragmented red
cells, fibrinogen and hemosiderin-laden macrophages with
background features of acute venous outflow obstruction.
Figure 2. Masson trichrome X 250 showing late stages of VOD.
Non-specific centrilobular fibrous scarring showing an ingrowth
of small vascular channels.
prostaglandin E1, pentoxifylline and ursodeoxy-
cholic acid.
The usefulness of low-dose heparin has been
shown in a prospective randomized study conduct-
ed by Attal,50 who compared a control group and a
group receiving heparin at a dose of 100 U/kg/d
from day –8 until day +30 after autologous and
allogeneic BMT. The incidence of VOD decreased
from 13.7% in the control group to 2.5% in the
heparin group. However, there was no difference in
the incidence of severe VOD which was very low in
both arms. In a double-blind, placebo-controlled
study in 61 patients undergoing autologous or allo-
geneic BMT, the low molecular weight heparin
enoxaparin was shown to significantly reduce the
incidence and duration of VOD, but severe VOD
was not reported in the placebo group.51 In addi-
tion, platelet engraftment was accelerated, platelet
transfusion was reduced, and hemorrhagic events
were less frequent and less severe in the treated
group. Thus, although the administration of low-
dose heparin appears to be safe, it remains to be
shown in a large randomized trial that severe VOD
can be prevented in high-risk patients.
In 1989, Gluckman52 reported a study in which
prostaglandin E1 (PGE1) was administered at a
dose of 3 µg/kg/h from the start of the preparative
regimen until day 30 post-transplant in leukemic
patients undergoing allogeneic BMT. The incidence
of VOD decreased from 39.1% in the historical con-
trol group to 12.8% in the treated group, most
notably in patients with previous hepatitis.
However, others53 were not able to reproduce these
results in patients at high risk of VOD, and noted
considerable toxicity precluding full completion of
the treatment.
Pentoxifylline (PTX) is a methylxanthine analogue
which can inhibit transcription of TNF-a. In a non-
randomized study, the administration of PTX con-
siderably reduced the incidence of VOD and other
toxicities compared to historical controls.1 6
However, randomized prospective studies have
failed to show any advantage of PTX in the preven-
tion of VOD or other toxicities associated with
BMT.54
Ursodeoxycholic acid, an artificial bile acid, pro-
tects hepatocytes from damage caused by cholesta-
sis. Essell55 reported a low incidence of VOD in
patients receiving ursodeoxycholic acid prophylacti-
cally (which was fairly well tolerated). More recent-
ly, a prospective study by the same group56 showed
that patients randomized for ursodeoxycholic acid
developed significantly less VOD than patients
receiving the placebo.
Finally, when high-dose radiotherapy (>12 Gy) is
applied or when VOD occurs prior to completion of
TBI, liver shielding may be used to reduce hepatic
toxicity, although its efficacy is not demonstrated and
its effect on tumor eradication remains unknown.
Treatment
While more knowledge about the pathophysiolo-
gy of VOD has allowed for the proposal of such
prevention, it also lays the ground for therapeutic
measures, including supportive care, PGE1, r-tPA,
and liver transplantation.
Supportive care is aimed at maintaining intravas-
cular volume and renal perfusion while avoiding
extravascular fluid accumulation.11 This involves
restriction of the sodium supply and diuretic thera-
py with loop diuretics or spironolactone. Perfusion
of albumin concentrates or colloids can help main-
tain the intravascular volume, but will eventually
accumulate in extravascular spaces. Therefore, pref-
erence should be given the to transfusion of red
cells to maintain the hematocrit above 38-40%.
Several groups have advocated continuous perfu-
sion of dopamine to maintain renal blood flow, but
its real value has not been proven. Finally, when
fluid accumulation cannot be controlled, hemo-
dialysis is necessary. When ascites limit breathing,
paracentesis may be required. Encephalopathy
should be treated with protein restriction and oral
lactulose. The use of peritoneovenous shunts can
improve symptomatology, but runs a very high risk
of serious complications.
There are also approaches aimed at reversing
venular occlusion. There are only brief reports of
PGE1 improving established moderate VOD.11.
Recombinant tissue plasminogen activator (r-tPA)
has been used in several centers. The largest experi-
ence was reported by the Seattle57 group in 42
patients receiving 5 to 120 mg of r-tPA over 2-4
days together with low-dose heparin. Twelve (29%)
patients responded, but with a substantial risk of
serious bleeding. Non-responders included those
requiring supplemental oxygen, mechanical ventila-
tion or dialysis before the start of r-tPA. 
Defibrotide, a novel polydeoxyribonucleotide, has
several properties of potential interest for the treat-
ment of VOD, such as the increase of endogenous
tissue plasminogen activator and the decrease of
plasminogen activator inhibitor type 1. Richardson
et al.58 treated eight patients with severe VOD using
defibrotide. Complete responses were achieved in
three patients, none of whom had responded to r-
tPA.
Several groups have used portosystemic shunting
in order to decrease portal hypertension. Surgical
shunting is possible,59 but because few patients
with severe VOD are reasonable candidates for
surgery, the most interesting technique appears to
be transjugular intrahepatic portosystemic stent-
shunt (TIPS).60-62 This technique consists in creating
an intraparenchymal channel (kept permeable with
a metal stent) between a main branch of the portal
vein and a hepatic vein using a percutaneously
inserted transjugular catheter. Although TIPS
improved clinical status and liver function in a few
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patients, more extensive experience should be accu-
mulated on the risks and efficacy of the procedure.
Finally, as a last resort in case of life-threatening
hepatic failure, orthotopic liver transplantation can
be considered.63,64 However, very few patients who
have received a liver transplant for acute VOD have
become long-term survivors.11
Perspectives and conclusions 
VOD is a serious complication of high-dose regi-
mens used as conditioning before BMT, for which a
number of risk factors have been identified. We
favor the systematic use of low-dose heparin (100
U/kg/d) or low molecular weight heparin, starting
with the conditioning regimen and continuing
through day 21 post-transplant, in all patients
undergoing autologous or allogeneic BMT. For
patients particularly at risk for developing severe
VOD, we add ursodeoxycholic acid during the same
period. It is of utmost importance to identify signs
of VOD as early as possible, so that supportive care
can be adapted accordingly. The differential diag-
nosis with acute GVHD or liver infections is critical
because these complications may coexist, particu-
larly in allogeneic transplant recipients, and their
management is radically different and not devoid of
serious side effects. In this setting, a transjugular
measurement of HVPG and even a liver biopsy may
be needed when clinical diagnostic criteria such as
those proposed by the Seattle and Baltimore
groups are not met or when concomitant disorders
are suspected. Aggressive therapeutic intervention,
such as r-tPA 20-40 mg continuous infusion over 3-
4 days, should be initiated early (in order to avoid
multiorgan failure), but should be performed only
in those patients who could benefit from this in the
face of rapidly progressive VOD. Insertion of TIPS
by an experienced hand may be a valid option in
patients with major counter-indications or no
response to r-tPA, whereas the role of defibrotide
remains to be determined.
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